Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative cancer medicines targeting cell cycle, epigenetics, and mitosis biology. Its lead program, plogo, is a PLK1 inhibitor aimed at solid tumors and hematological malignancies. The company emphasizes targeted, oral therapies with potential for improved safety and efficacy, seeking strategic partnerships while retaining global rights to its drug candidates.
This description was generated via AI from an annual report. Updated about 1 year ago.